• Phase III CBD insomnia trial advances toward interim analysis
• Licensing agreement with Sandoz AG for CBD product commercialization in Australia
• $2.5 million raised to accelerate commercial manufacturing for CBD insomnia product

Avecho Biotechnology Limited continued dosing on its pivotal Phase III Clinical Trial for its proprietary TPM-enhanced CBD soft-gel capsule targeting insomnia. The trial was expanded with additional clinical trial sites and protocol amendments to increase recruitment. Towards the end of 2025, 190 patients had been dosed, representing the majority of the approximately 210 participants required for the planned interim analysis. In March 2025, the company entered into a licensing agreement with Sandoz AG for the exclusive commercialization rights of its TPM-enhanced CBD product in Australia. Avecho received an upfront payment of A$4.8 million and is eligible for future milestone payments and royalties. In October 2025, Avecho announced a $2.5 million capital raise from institutional and sophisticated investors to accelerate commercial manufacturing activities required to support a future TGA submission and commercial supply of the CBD insomnia product. The company's revenue for the year increased by 9.3% to $1,237,762, while the loss for the year increased by 41.5% to $4,416,623, typical of companies in the biotech sector at the company's stage of development.

Avecho is targeting completion of the interim analysis for its Phase III CBD insomnia trial in the first half of 2026, which is expected to represent a major clinical and commercial inflection point for the program.